PERIPHERAL PLASMA IMMUNOREACTIVE 6-OXO-POSTAGLANDIN F\textsubscript{1α} AND GYNAECOLOGICAL TUMOURS

M. ALAM, M. JOGEE, W. G. MACGREGOR, J. W. DOWDELL, M. G. ELDER AND L. MYATT

From the Institute of Obstetrics and Gynaecology, Hammersmith Hospital, Du Cane Road, London W12 0HS

Received 14 September 1981  Accepted 3 November 1981

Summary.—Peripheral plasma levels of immunoreactive 6-oxo-PGF\textsubscript{1α}, the stable hydrolysis product of prostacyclin, were significantly higher in female patients with tumours of the genital tract than in normal controls. In the groups with malignant tumours, these high levels declined after operation and/or radiotherapy if the tumour responded to treatment. In patients who did not respond to treatment or with tumour recurrence, levels of plasma 6-oxo-PGF\textsubscript{1α} remained high or even rose further. Benign gynaecological tumours were also associated with significantly raised plasma 6-oxo-PGF\textsubscript{1α} levels, and these fell to normal levels immediately on surgical removal of the tumour. Possible reasons for these alterations are described. Further investigations are warranted to see whether serial measurements of plasma 6-oxo-PGF\textsubscript{1α} could be used as a prognostic index for the clinical status of patients with gynaecological tumours.

The presence of prostaglandins in virtually all cell types so far studied and their potent biological activity has prompted their study in patients with malignant tumours. Increased synthesis of prostaglandins by tumour tissues of thyroid (Williams et al., 1968), phaeochromocytoma and bronchus (Sandler et al., 1968), kidney (Cummings & Robertson, 1977), breast (Bennett et al., 1975) and endometrium (Singh et al., 1976; Willman et al., 1976) have been described. Raised plasma levels of prostaglandins or their metabolites have been measured in the peripheral circulation and across the tumour bed in patients with both genital tract and breast tumours (Sanders et al., 1980; Powles et al., 1977; Stamford et al., 1980, derived from Mortel et al., 1977). This has led to the suggestion that plasma prostaglandin measurements might be a potentially useful tumour marker.

Prostacyclin (PGI\textsubscript{2}), a very potent vasodilator and anti-platelet-aggregating agent, is the major product of the cyclooxygenase enzyme pathway in a variety of tissues (Moncada & Vane, 1979). Unlike the primary prostaglandins, PGI\textsubscript{2} is neither metabolized by the lung (Hawkins et al., 1978) nor is it formed \textit{in vitro} during blood sampling and preparation. Prostacyclin is spontaneously hydrolysed to 6-oxo-PGF\textsubscript{1α}, a metabolite which has been used extensively as a measure of PGI\textsubscript{2} production. Khan et al. (1980) have found significantly raised levels of plasma 6-oxo-PGF\textsubscript{1α} in patients with malignant prostatic disease. In this preliminary study we have measured plasma 6-oxo-PGF\textsubscript{1α} in patients with a variety of gynaecological tumours, and examined serial changes after surgery and/or chemotherapy or radiotherapy and at short-term follow-up.

Patients and Methods

Twenty patients formed the control group. Ten of these underwent major gynaecological surgery for conditions other than a tumour, and 10 were being treated medically for minor problems such as vaginitis.

Of the 52 patients with gynaecological
tumours, 15 had benign tumours and 37 malignant tumours. Of the benign-tumour group 12 had uterine fibroids and 3 had an ovarian cyst. The malignant group consisted of carcinoma of the ovary (17), carcinoma of the cervix (16) and carcinoma of the uterus (4).

Venous blood (5 ml) was taken from the antecubital vein into EDTA and immediately centrifuged at 1500 g for 10 min at 4°C. Plasma was separated and stored at −20°C. Levels of 6-oxo-PGF₁α were assayed by specific radioimmunoassay (Myatt et al., 1981) within 4 weeks of collection. Collection of blood into indomethacin gave similar values to that collected in EDTA. Therefore, artefactual in vitro formation of PGI₂ did not influence the results. As radioimmunoassay cannot be entirely specific, the results are expressed as immunoreactive plasma 6-oxo-PGF₁α equivalents, and serial changes in immunoreactive 6-oxo-PGF₁α were measured. Where applicable, blood samples were collected as follows:

(i) 24 h before operation or start of radiotherapy,
(ii) On the 7th or 8th postoperative day,
(iii) During the 6th or 7th week after surgery or radiotherapy,
(iv) 12 weeks after start of radiotherapy.

All samples were collected between 10:00 and 12:00. None of the patients were given any analgesics known to inhibit prostaglandin synthesis (e.g. aspirin and other non-steroidal anti-inflammatory drugs).

The statistical differences between mean 6-oxo-PGF₁α levels of the various groups was assessed by Wilcoxon’s rank sum test or, within the same group, by Wilcoxon’s signed rank test for nonparametric statistics.

**RESULTS**

The plasma immunoreactive 6-oxo-PGF₁α levels in the various study groups are shown in Tables I & II.

**Control group**

Plasma 6-oxo-PGF₁α levels of 93 ± 32 pg/ml (mean ± s.d.) in the control group were similar to those previously measured in normal subjects (Myatt et al., 1981); the mean postoperative value of 103 ± 30 pg/ml found in the 10 patients who underwent major gynaecological surgery for a non-malignant condition was not significantly different from that of the control values.

**Benign tumour group**

The pre-operative plasma 6-oxo-PGF₁α levels were significantly higher (*P < 0.05*) in this group than in the control group. After removal of the tumour, high 6-oxo-PGF₁α levels fell to the normal range in all the patients (Fig. 1). With both fibroids and ovarian cysts there appeared to be a direct relationship between the size of the tumour as assessed clinically and the increase in plasma 6-oxo-PGF₁α levels.

**Malignant tumour group**

**Carcinoma of the cervix.—** In 11 patients with Stage 0 carcinoma of the cervix,
plasma 6-oxo-PGF$_{1\alpha}$ levels were significantly raised ($P<0.01$) at the time of diagnosis (Table I). After a total hysterectomy and during subsequent follow-up, plasma 6-oxo-PGF$_{1\alpha}$ levels were comparable to those of controls. The 5 patients with Stage I–IV disease had raised levels of plasma 6-oxo-PGF$_{1\alpha}$ but unrelated to Stage. The rise was not statistically significant, perhaps due to the small number of patients. After radiotherapy all these patients improved clinically, whilst their plasma 6-oxo-PGF$_{1\alpha}$ levels had fallen slightly by 6 weeks, and to the normal range by 3 months (80 ± 28 pg/ml; Table I).

**Carcinoma of the ovary and uterus.**—
There were 17 patients with carcinoma of the ovary in this group, with disease ranging from Stage Ia to IV (FIGO), and 4 with carcinoma of the uterus.

The changes in plasma 6-oxo-PGF$_{1\alpha}$ levels in both groups of patients were dependent on the clinical outcome. In view of the few carcinomas of the uterus, both groups were combined for analysis. Pre-operative plasma 6-oxo-PGF$_{1\alpha}$ levels were significantly high, both those responsive and those irresponsive to therapy (Table II) but with no significant difference between these two groups.

**Responders**

In 12 patients with carcinoma of the ovary the operation was total abdominal hysterectomy, bilateral salpingo-oophorectomy, removal of tumour and omentectomy, followed by chemotherapy. All 12 responded to treatment and are alive, and their 6-oxo-PGF$_{1\alpha}$ levels had fallen considerably after surgery and at follow-up (Fig. 2). Of the 7 cases available for follow-up, 3 were studied more closely. In these patients plasma 6-oxo-PGF$_{1\alpha}$ levels fell postoperatively (Fig. 2) but a subsequent rise was seen while they were awaiting chemotherapy. Once chemotherapy was started, plasma 6-oxo-PGF$_{1\alpha}$ levels fell, with concurrent clinical improvement in all patients.

Three of the 4 patients with carcinoma of the uterus were operable, responded to radiotherapy, and are alive and well. Both postoperatively and after radio-

**Table II.—Plasma immunoreactive 6-oxo-PGF$_{1\alpha}$ in patients with carcinoma of the ovary and uterus**

| Outcome               | Median age (range) | Mean ± s.d. plasma 6-oxo-PGF$_{1\alpha}$ equivalents (pg/ml) |
|-----------------------|--------------------|-------------------------------------------------------------|
|                       |                    | Pre-op  | Post-op   | Follow-up |
| (a) Responders (n=15) | 57.5 (40)          | 267± 55** | 199±38** | 141±72    |
| (b) Non-responders (n=6) | 71.5 (15)     | 202±103** | 175±123  | 225±66*** |

Postoperative samples were taken at 7–8 days after operation and follow-up samples at 6–7 weeks. Significance of differences * $P<0.05$, ** $P<0.01$, *** $P<0.001$, as in Table I.
therapy, plasma 6-oxo-PGF$_{1\alpha}$ levels fell to normal. In the combined group of responsive patients, significant reductions of plasma 6-oxo-PGF$_{1\alpha}$ occurred in the postoperative and follow-up periods (Table II). Although the levels were still significantly higher than normal postoperatively, they had fallen to within the normal range at follow-up.

Non-responders

Five patients with carcinoma of the ovary and one with carcinoma of the uterus were found to be inoperable. None of these responded to chemotherapy and all subsequently died. The mean plasma 6-oxo-PGF$_{1\alpha}$ levels were significantly raised before laparotomy (Table II), were not significantly affected by chemotherapy, and were still significantly above normal at follow-up. This contrasted with the group of patients who responded to therapy, in all of whom plasma 6-oxo-PGF$_{1\alpha}$ fell.

**DISCUSSION**

Plasma 6-oxo-PGF$_{1\alpha}$ levels in the control group of patients were not altered by major surgery. To our knowledge no other study has shown an increase in prostaglandin production associated with a benign tumour. The apparent relationship between benign tumour size (fibroid or ovarian cyst) and plasma 6-oxo-PGF$_{1\alpha}$ suggested either that the tumour produced and released PGI$_2$ into the peripheral circulation or that increased PGI$_2$ production may be associated with the increased vascular supply to these tumours. Plasma 6-oxo-PGF$_{1\alpha}$ levels rise during normal pregnancy, perhaps in association with the increased uterine vascularity (Bolton et al., in press).

Primary prostaglandin concentrations are increased in plasma (Sanders et al., 1980), tumour tissues (Singh et al., 1976; Willman et al., 1976) and across the tumour bed (Stamford et al., 1980, derived from Mortel et al., 1977) in patients with gynaecological tumours. The lack of PGI$_2$ metabolism by the lung (Hawkins et al., 1978), and its spontaneous hydrolysis in plasma to 6-oxo-PGF$_{1\alpha}$, which has a relatively
long half-life, both facilitates measurement and makes plasma measurements more meaningful than for the primary prostaglandins.

In contrast to Sanders et al. (1980), who measured peripheral plasma PGF, we found no correlation between either tumour type or stage of differentiation and plasma 6-oxo-PGF<sub>1α</sub> levels. However, other reports show a conflict over the correlation between tumour differentiation and PG production (Khan et al., in press; Bennett et al., unpublished; Rolland et al., 1980).

Plasma 6-oxo-PGF<sub>1α</sub> levels fell in cases of carcinoma of the ovary or uterus after surgery, or if the tumour subsequently responded to chemotherapy or radiotherapy, but rose in all patients whose tumours did not respond to therapy. The clinical progression of such tumours may perhaps be monitored, though the origin of the increased 6-oxo-PGF<sub>1α</sub> is uncertain. Our observations on the carcinoma of the ovary group suggest that chemotherapy should be started as soon as possible. The differences between chemotherapy-responsive and non-responsive patients with carcinoma of the ovary suggest that a reduction in plasma 6-oxo-PGF<sub>1α</sub> is secondary to tumour regression rather than a direct effect of chemotherapy on the prostaglandin synthetic pathways.

The findings of significantly raised plasma 6-oxo-PGF<sub>1α</sub> levels in patients with Stage 0 squamous carcinoma of the cervix are initially surprising, in view of the microscopic tumours. Rather than producing PGF<sub>1α</sub>, these cells may be releasing factors that alter PGF<sub>1α</sub> synthesis or metabolism at other locations. Treatment of Stage 0 carcinoma of the cervix produced a more rapid fall of 6-oxo-PGF<sub>1α</sub> than in carcinoma of the ovary or uterus. The more advanced cases of carcinoma of the cervix (Stage I–IV) with increased vascular involvement were not associated with further increases in pre-treatment plasma 6-oxo-PGF<sub>1α</sub> levels. The slower fall in 6-oxo-PGF<sub>1α</sub> in these patients after radiotherapy may indicate a slower rate of tumour regression. However, the inflammatory response of irradiated tissues may stimulate PGF<sub>1α</sub> production (Tanner et al., 1981) which masks the fall in production by tumour tissue. Therefore in these patients plasma 6-oxo-PGF<sub>1α</sub> may not be initially such an accurate marker for the clinical response of the tumour itself, though it undoubtedly is at follow-up.

Our findings add to the weight of evidence for increased plasma prostaglandin levels in cancer patients. Serial measurements of 6-oxo-PGF<sub>1α</sub> may, with some reservations such as treatment with radiotherapy, provide a useful guide to the clinical progression of the disease, though they have to be used with caution to diagnose malignancy. In vitro experiments, more invasive sampling techniques and a larger study are needed to clarify the source of prostaglandin, or its possible correlation with disease stage. The potent vasodilator and platelet-anti-aggregation properties of prostacyclin bring into question its role in dissemination of cancer.

REFERENCES

Bennett, A., McDonald, A. M., Simpson, J. S. & Stamford, I. F. (1975) Breast cancer, prostaglandins and bone metastases. Lancet, i, 1218.

Bolton, P., Jogee, M., Myatt, L & Elder, M. G. (in press) Prostacyclin in maternal circulation throughout pregnancy. A longitudinal study. Br. J. Obstet. Gynaecol.

Cummings, K. D. & Robertson, R. P. (1977) Prostaglandin increased production by renal cell carcinoma. J. Urol., 118, 720.

Hawkins, H. J., Smith, J. B., Nicolaou, K. C. & Eling, T. D. (1978) Studies on the mechanism involved in the fate of prostacyclin (PGE<sub>2</sub>) and 6-keto-PGF<sub>1α</sub> in the pulmonary circulation. Prostaglandins, 16, 871.

Khan, O., Hensby, C. N. & Williams, G. (1980) Prostaglandin levels in patients with prostatic cancer monitoring growth and spread of disease. Br. J. Surg., 67, 825.

Khan, O., Hensby, C. N. & Williams, G. (in press) Prostacyclin in prostatic cancer. A better marker than bone scan or serum acid phosphatase? Br. J. Urol.

Moncada, S. & Vane, J. R. (1979) Prostaglandin formation and effects. In Chemistry, Biochemistry and Pharmacological Activity of Prostaglandins. (Eds Roberts & Scheimann). Oxford: Pergamon Press. p. 258.
PLASMA 6-OXO-PGF₁α AND GYNAECOLOGICAL TUMOURS

MORTEL, R., ALLEGRA, J. C., DEMERS, L. M. & 6 others (1977) Plasma prostaglandins across the tumour bed of patients with gynecologic malignancy. Cancer, 39, 2201.

MYATT, L., JOGEE, M., LEWIS, P. J. & ELDER, M. G. (1981) Metabolism of prostacyclin and 6-oxo-PGF₁α in man. In Clinical Pharmacology of Prostacyclin. (Ed. Lewis & O'Grady), New York: Raven Press. p. 25.

POWLES, T. J., COOMBES, R. C., MUNRO-NEVILLE, A., FORD, H. T., GAZET, J. C. & LEVINE, L. (1977) 15-Keto-13, 14-dihydro prostaglandin E₂ concentrations in serum of patients with breast cancer. Lancet, ii, 138.

ROLLAND, P. H., MARTIN, P. M., JACQUEMIER, J., ROLLAND, A. M. & TOGA, M. (1980) Prostaglandin in human breast cancer: Evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. Natl Cancer Inst., 64, 1081.

SANDERS, R. R., LEE, W. H., KOH, L., BRENNERCE, A. & JONES, W. R. (1980) Plasma prostaglandin F levels and malignant tumours of the female genital tract. Br. J. Obstet. Gynaecol., 87, 139.

SANDLER, M., KARIM, S. M. M. & WILLIAMS, E. D. (1968) Prostaglandins in amine peptide secreting tumour. Lancet, ii, 1063.

SINGH, E. J., BACCARRINI, I. M. & ZUSPAN, F. P. (1976) Levels of prostaglandin F₂ and E₂ in human endometrium during the menstrual cycle. Am. J. Obstet. Gynecol., 121, 1003.

STAMFORD, I. F., MACINTYRE, J. & BENNETT, A. (1980). Human breast carcinomas release prostaglandin-like material into the blood. In Advances in Prostaglandin and Thromboxane Research, Vol. 6, (Ed. Samuelson et al.). New York: Raven Press. p. 571.

TANNER, N. S. B., STAMFORD, I. F. & BENNETT, A. (1981) Plasma prostaglandins in mucositis due to radiotherapy and chemotherapy for head and neck cancer. Br. J. Cancer, 43, 787.

WILLIAMS, E. D., KARIM, S. M. M. & SANDLER, M. (1968) Prostaglandin secretion by medullary carcinoma of the thyroid. Lancet, i, 22.

WILLMAN, E. A., COLLINS, W. P. & CLAYTON, S. G. (1976) Studies in the involvement of prostaglandins in uterine symptomatology and pathology. Br. J. Obstet. Gynaecol., 83, 337.